Vaccine Promising for Multiple Cancer Indications

Sellas Life Sciences announced top-line data from the Phase 2 clinical study of its WT1 cancer vaccine in patients with malignant pleural mesothelioma (MPM).

Blod Test for Cancer Relapse Promising

An experimental blood test may one day detect the return of early-stage breast cancer months before it is revealed by computed tomography or magnetic resonance imaging.

Odomzo Approved for Advanced Skin Cancer

The FDA has approved Odomzo (sonidegib) capsules for the treatment of adults with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

Cancer Patients Need Fertility Preservation Awareness

Many young cancer patients have limited awareness about options to preserve their fertility.

ED Drugs and Melanoma Risk

Patients taking medications for erectile dysfunction (ED) may have an increased risk of melanoma but these drugs are not a cause of melanoma.

Chili Pepper Toxin, Gallbladder Cancer Risk

Gallbladder cancer seems to be associated with aflatoxin, according to a new study.

No Link Between PTSD, Cancer

While the potential relationship between stress and cancer has been a topic of discussion and research for over 70 years, no association between post-traumatic stress disorder (PTSD) and cancer was found in the largest study to date.

Cyramza Gains Colon Cancer Indication

The FDA has expanded the indication of Cyramza (ramucirumab; Eli Lilly) for use in combination with irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed on a first line bevacizumab-, oxaliplatin- and fluoropyrimidine-containing regimen.


Portrazza Approved for Metastatic Squamous NSCLC

Portrazza Approved for Metastatic Squamous NSCLC

The FDA has approved Portrazza (necitumumab injection) in combination with gemcitabine and cisplatin as first-line treatment for patients with metastatic squamous non-small cell lung cancer (NSCLC) who have not previously received medications for their advanced lung cancer.

FDA Approves Two New Indications for Opdivo

FDA Approves Two New Indications for Opdivo

The FDA has approved Opdivo (nivolumab) to treat patients with metastatic renal cell carcinoma who have received prior anti-angiogenic therapy and as a single agent to treat patients with BRAFV600 wild-type unresectable or metastatic melanoma.

USPSTF Calls for More Research in These 5 Women's Health Issues

USPSTF Calls for More Research in These 5 Women's Health Issues

The United States Preventive Services Task Force (USPSTF) released its annual Report to Congress reporting on 5 high-priority evidence gaps regarding women's health.

Ninlaro Approved for Multiple Myeloma

Ninlaro Approved for Multiple Myeloma

The FDA has approved Ninlaro (ixazomib; Takeda) capsules in combination with lenalidomide (Revlimid; Celgene) and dexamethasone for the treatment of patients with multiple myeloma who have received at least 1 prior therapy.

Novel Tx Granted Orphan Drug Status for Aggressive Brain Cancer

The FDA has granted Orphan Drug designation to marizomib (Triphase Accelerator) for the treatment of malignant glioma, an aggressive form of brain cancer with a significant unmet need due to its poor prognosis.


Make prescribing decisions with our comparative charts and treatment algorithms.

Patient Information Fact Sheets

Download or print easy-to-read disease leaflets for your patients.

Featured courses from myCME

Comprehensive Review of Radiation OncologyExternal web site

Led by renowned faculty Program Director Christopher G. Willett, MD, this review focuses on therapies ...

CME 24.00 Credits

Pathology APB Examination Question BankExternal web site

Stay current and study for the Pathology Re-Certification Exam with over 1,200 practice radiology questions. ...


Pain Medicine ABPM/ABA Examination Question BankExternal web site

Access more than 700 pain medicine practice questions and review detailed rationales for each answer. ...


Sign Up for Free e-newsletters